Mu, Jingxi
Maeda, Keiko
Ohashi, Ayako
Urano, Takeshi
Nariai, Yuko
Kamino, Hiroki
Nakamura, Masanao
Yamamura, Takeshi
Sawada, Tsunaki
Ishikawa, Eri
Murate, Kentaro
Yamamoto, Kenta
Hirose, Takashi
Furukawa, Kazuhiro
Fujishiro, Mitsuhiro
Kawashima, Hiroki
Funding for this research was provided by:
JST SPRING (JPMJSP2125)
Japan Society for the Promotion of Science (JSPS) KAKENHI grant (JP21K5920)
Japan Agency for Medical Research and Development (A138)
Moonshot Research and Development Program (JPMJMS2214-11)
Nagoya University
Article History
Received: 8 March 2024
Accepted: 16 April 2024
First Online: 7 May 2024
Declarations
:
: TU is an employee at Shimane University and is the co-founder and current Chief Medical and Scientific Officer of mAbProtein, a biotechnology company that focuses on the development and commercial use of mAbs in inflammation research, diagnosis, and treatment. The potential conflicts of interest of TU do not alter the authors’ adherence to any of the journal policies on sharing data and materials. The other authors declare no potential conflicts of interest.
: Animal experiments were approved by the Animal Care and Use Committee of Nagoya University Graduate School of Medicine (approval number: M230086) and performed in compliance with the regulations and guidelines of animal care and use in Nagoya University. All the experiments were performed and reported in accordance with ARRIVE guidelines. The human study was conducted following the Declaration of Helsinki for Human Research, and protocols were approved by the Research Ethics Committee of Nagoya University (approval number: 2018-0316).
: All participants provided written informed consent to participate in the study.
: Not applicable.